AI is accelerating drug discovery by closing a critical feedback loop that traditional methods leave open. Pharmaceutical development currently costs $2.6 billion on average and takes over a decade. Eroom's Law, the inverse of Moore's Law, shows drug development costs have doubled roughly every nine years since the 1950s. This trend reflects both the complexity of identifying effective compounds and the regulatory burden of clinical validation.

The bottleneck lies in data. Researchers test thousands of compounds in labs, generating results that rarely feed back into the AI models guiding future searches. Each experiment produces valuable information about molecular behavior, toxicity, and efficacy, but this data sits in databases disconnected from discovery algorithms. The gap means AI systems train on historical data alone, missing real-time feedback on what actually works.

Closing this loop means AI models learn from every experiment conducted. When a compound fails or succeeds in the lab, that outcome immediately informs the next generation of predictions. Researchers at MIT and other institutions are building systems that automatically incorporate experimental results into machine learning models, creating a continuous learning cycle.

The practical impact is substantial. Tighter feedback loops reduce the number of compounds that need synthesis and testing. Companies can prioritize the most promising candidates earlier in development. This compressed timeline matters enormously in a market where first-mover advantage determines commercial success and patient access timelines.

The approach also addresses data quality challenges. AI models trained on curated experimental data from a single company's pipeline learn patterns specific to that organization's chemistry and biology. This produces more accurate predictions for internal use than models trained on aggregated public datasets.

Integration challenges remain real. Labs use different equipment, protocols, and data formats. Standardization across organizations is slow. Patent concerns limit data sharing between competitors. Yet the pressure from Eroom's Law forces change. Drug developers cannot sustain current costs. AI-driven feedback loops represent one of